D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $2 price target.
- Headlines
- D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
15:07
Europe's Henry Hub Natural Gas reserves are being consumed at the fastest rate since 2018.
15:06
Most Nonprofit Pharmaceutical Companies in the Hong Kong stock market rose: Lakai Pharma and Cloud Top New Industry increased by over 7%.
LAEKNA-B+5.74%
15:06
According to data from the Shanghai Exchange, as of January 6, 2025, the Shanghai Export Container Settlement Index (Europe route) is reported at 3387.69 points, a decrease of 3.6% compared to the last period.